An Implantable Microstimulator for the Treatment of Chronic Shoulder Pain in Chronic Post-Stroke Subjects (BBPM)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2011 by Bioness Inc.
Recruitment status was  Active, not recruiting
Information provided by (Responsible Party):
Bioness Inc Identifier:
First received: December 3, 2007
Last updated: November 14, 2011
Last verified: November 2011

The goal of this research study is to investigate the safety and effectiveness of a new implanted device designed to treat chronic shoulder pain in chronic post-stroke subjects. The BBPM weighs less than 0.03 ounces and measures 1" x 0.1". It is implanted into the shoulder to stimulate the axillary nerve. Stimulation of this nerve may reduce shoulder pain, reduce shoulder subluxation, improve motion, improve function, and decrease use of pain medication. CAUTION--Investigational device. Limited by Federal law to investigational use.

Condition Intervention Phase
Chronic Shoulder Pain in Chronic Post-Stroke
Device: Bioness Battery Powered Microstimulator
Device: Battery-Powered Microstimulator (BBPM)
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Feasibility Study of the Bioness Battery-Powered Microstimulator (BBPM) to Treat Chronic Shoulder Pain in Chronic Post-Stroke Subjects

Further study details as provided by Bioness Inc:

Primary Outcome Measures:
  • The primary outcome measure will be the feasibility of using the BBPM for treatment of chronic shoulder pain as evidenced by appropriate muscular contraction and/or paresthesias with no significant adverse events. [ Time Frame: From baseline to follow up ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Greater than 30% Pain Reduction measured by using Brief Pain Inventory (BPI #12) at each time point without increasing pain medication -Range of motion will be quantified using a goniometer -Motor functions will be measured by Fugl-Meyer Test [ Time Frame: From baseline to follow-up ] [ Designated as safety issue: No ]
  • Range of Motion: pain-free passive shoulder abduction, flexion and external rotation will be quantified. [ Time Frame: baseline to end of study ] [ Designated as safety issue: No ]
  • -Interference of shoulder pain in daily activities and function measured by using BPI#23 -Quality of Life assessed by using he EuroQol -Reported use of pain medication -Examined for shoulder subluxation -Examined for cutaneous shoulder sensation [ Time Frame: baseline to end of study ] [ Designated as safety issue: Yes ]

Enrollment: 16
Study Start Date: June 2007
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Therapeutic Stim Grp
The BBPM is programmed to deliver set therapeutic stimulation parameters for the first 12 weeks of the study.
Device: Bioness Battery Powered Microstimulator
The BBPM will be programmed for the first 12 weeks of the study to deliver electrical stimulation for treatment of post-stroke shoulder pain.
Placebo Comparator: Sham Stim Grp
The BBPM will be programmed for the first 12 weeks of the study to deliver short bursts of extremely low amplitude electrical stimulation at very wide time intervals to give appearance, impression, and sensation of therapeutic treatment. After 24 weeks, they will be reprogrammed to receive therapeutic stimulation.
Device: Battery-Powered Microstimulator (BBPM)
The BBPM will be programmed for the first 12 weeks of the study to deliver short bursts of extremely low amplitude electrical stimulation at very wide time intervals to give appearance, impression, and sensation of therapeutic treatment. After 24 weeks, they will be reprogrammed to receive therapeutic stimulation.

Detailed Description:

This is a prospective, dual-center, randomized, controlled, double-blinded parallel study designed to evaluate the feasibility and safety of using the The primary purpose of this study is to demonstrate the clinical feasibility of implanting the BBPM near a peripheral nerve for the treatment of chronic, intractable, pain in this case represented by chronic regional shoulder pain in hemiplegic stroke patients. This is a 48-week study with a two-year follow up.


Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years of age or older
  • Chronic post-stroke duration greater than or equal to 6 months
  • Unilateral hemiplegic shoulder pain persisting for ≥6 months
  • Hemiparesis (shoulder abduction graded <5/5 on Manual Muscle Testing ipsilateral to the shoulder in which the subject has chronic pain
  • Shoulder pain ≥ 6/10 (on 0-10 numeric rating scale (NRS) for worst pain in last week (BPI #12))
  • Ability to give informed consent and understand study requirements
  • Ability to quantify pain using a 0-10 numeric rating scale. (A screening tool will be used to ensure that participants can rate 3 common pain scenarios (mosquito bite, stubbed toe and broken bone) on a 0-10 NRS relative to each other.)
  • Willing and able to understand and comply with all study-related procedures during the course of the study
  • Motivated to maintain an accurate diary for the study duration

Exclusion Criteria:

  • Hemineglect (i.e., extinguish to double simultaneous stimulation)
  • Shoulder trauma or diagnosed shoulder pathology prior to stroke; history of any shoulder surgery, regardless of whether procedure preceded for followed stroke.
  • Need to take >1 pain medication (opioid or non-opioid) for shoulder pain
  • Regular use of pain medication for chronic pain other than shoulder pain
  • Anticoagulated (taking warfarin or heparin, including fractionated heparin) or has a bleeding disorder
  • Unable, per their prescribing physician, to stop antiplatelet medications (e.g., aspirin, ticlopidine (Ticlid), clopidogrel (Plavix), tirofiban (Aggrastat), and eptifibatide (Integrilin)) for at least 7 days prior to device implantation.
  • Cardiac pacemaker
  • Implanted neurostimulator (e.g., spinal cord, deep brain, vagus nerve) or implanted pump or infusion device
  • Prosthetic heart valve or valvular heart disease requiring antibiotic prophylaxis
  • History of cardiac arrhythmia with hemodynamic instability
  • Uncontrolled seizures (> 1 seizure per month)
  • Pregnant or plan on becoming pregnant during the study period
  • Medical instability
  • Currently require, or likely to require, diathermy
  • Currently require, or anticipated to require, MRI within 8 weeks of projected device implantation date
  • History of adverse reactions to local anesthetic (e.g., lidocaine)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00567541

United States, California
Rancho Los Amigos National Rehabilitation Center
Downey, California, United States, 90242
United States, Washington
Virginia Mason Medical Center
Seattle, Washington, United States, 98101
United States, West Virginia
The Center for Pain Relief
Charleston, West Virginia, United States, 25301
Sponsors and Collaborators
Bioness Inc
Principal Investigator: Andrew Friedman, MD Virginia Mason Seattle Main Clinic
Principal Investigator: Tim Deer, MD The Center for Pain Relief
Principal Investigator: Ziyad Ayyoub, M.D. Rancho Los Amigos National Rehabilitation Center
  More Information

No publications provided

Responsible Party: Bioness Inc Identifier: NCT00567541     History of Changes
Other Study ID Numbers: CP-BBPM-001
Study First Received: December 3, 2007
Last Updated: November 14, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Bioness Inc:

Additional relevant MeSH terms:
Shoulder Pain
Brain Diseases
Cardiovascular Diseases
Central Nervous System Diseases
Cerebrovascular Disorders
Joint Diseases
Musculoskeletal Diseases
Nervous System Diseases
Signs and Symptoms
Vascular Diseases processed this record on July 29, 2015